Although there is overwhelming evidence that survivin is an important therapeutic target in disparate tumors, including breast cancer[44], the portfolio of survivin antagonists suitable to target this pathway in the clinic has remained disappointingly narrow[15]. Here, BIRC5 is linked to breast cancer.